行情

GERN

GERN

杰龙公司
NASDAQ

实时行情|Nasdaq Last Sale

1.080
+0.030
+2.86%
盘后: 1.110 +0.03 +2.78% 18:04 04/08 EDT
开盘
1.060
昨收
1.050
最高
1.100
最低
1.010
成交量
146.97万
成交额
--
52周最高
2.140
52周最低
0.7500
市值
2.16亿
市盈率(TTM)
-3.0252
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测GERN价格均价为3.300,最高价位4.000,最低价为3.000。

EPS

GERN 新闻

更多
  • Geron to Present at Needham Virtual Healthcare Conference
  • GlobeNewswire · 7小时前
  • Here's Why We're Not Too Worried About Geron's (NASDAQ:GERN) Cash Burn Situation
  • Simply Wall St. · 15小时前
  • 解码物流“新基建”:全链条迎数字化新生
  • 新浪科技综合 · 2天前
  • The Geron Saga: COVID-19 Edition
  • Seeking Alpha - Article · 3天前

所属板块

生物技术和医学研究
+3.06%
制药与医学研究
+2.82%

热门股票

代码
价格
涨跌幅

GERN 简况

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.
展开

微牛提供Geron Corporation(NASDAQ-GERN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的GERN股票新闻,以帮助您做出投资决策。